NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $471 million acquisition of German diagnostics firm Brahms, the firm said today.
Thermo Fisher initially announced the deal in early September. The acquisition will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.
Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.
Thermo said that Brahms will be integrated into its Analytical Technologies segment. It will use Brahms' former headquarters in Hennigsdorf, Germany, as the European Center of Excellence for its clinical diagnostics business.